ISAL 2023 | Clinical and prognostic significance of aberrant T-cell marker expression in AML
Inna Shaforostova, MD, University Hospital Münster (UKM), Münster, Germany, discusses a retrospective study which evaluated the clinical and prognostic significance of aberrant T-cell marker expression in acute myeloid leukemia (AML). In this study, researchers evaluated the expression of various T-cell markers, including CD2, CD4, CD7 and TdT, and analyzed the association of these markers with disease specific characteristics and survival outcomes. Results demonstrated that CD2 expression was associated with abnormal non-complex karyotype with TP53 mutation and adverse risk, and CD2 and TdT were also associated with lower complete remission (CR) rates. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
